Overcoming radioresistance with the hypoxia-activated prodrug CP-506: a pre-clinical study of local tumour control probability.

CP-506 - Convert Pharma

carboplatin - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/37315579

Ala Yaromina; Alexander M A van der Wiel; Lesley Schuitmaker; Ludwig J Dubois; Lydia Koi; Mechthild Krause; Philippe Lambin

Jun 16, 2023